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ecent years have seen an explo-
sion of interest in the primary 
cilium. This long-neglected organ-
elle was widely considered to be an evolu-
tionary dead end before its critical function 
in cell signaling began to be uncovered. The 
microtubule-based membrane protrusion 
is now thought of as a cellular antenna, 
receiving extracellular signals and trans-
mitting them to the rest of the cell. Defects 
in cilia function cause a variety of diseases, 
collectively known as ciliopathies.
Maxence Nachury admits that he hadn’t 
even heard of the primary cilium until a few 
years ago when he was a postdoc with Peter 
Jackson at Stanford University and Genen-
tech. Before that, Nachury had studied both 
nuclear transport and mitotic spindle assem-
bly as a PhD student with Karsten Weis and 
Rebecca Heald at UC Berkeley (1, 2). But 
the mysterious primary cilium grabbed 
Nachury’s attention when he realized that 
mutations in a number of different ciliary 
proteins caused the pleiotropic human disor-
der Bardet-Biedl syndrome (BBS). Despite 
his initial unfamiliarity with 
the subject, Nachury soon 
demonstrated that seven of 
these proteins form a con-
served complex called the 
BBSome that transports 
membrane proteins to the cil-
ium (3). Nachury then identi-
fi   ed an additional BBSome 
subunit required for both cilia 
formation and microtubule 
acetylation (4). Now with his 
own lab at Stanford Univer-
sity, Nachury recently showed that the 
BBSome acts as a membrane coat to traf-
fi  c signaling receptors into the cilium (5).
In a recent interview, Nachury discussed 
the BBSome’s function and the cilium’s 
contribution to human disease.
CILIARY BASE
Where did you grow up?
I grew up in a fairly well-off suburb of Paris. 
I had a phenomenal biology teacher during 
high school, who helped me appreciate that 
what I was learning in physics and chem-
istry classes also applied to nature. It was 
the idea of understanding life in terms of 
basic molecular and physical principles 
that got me hooked on science.
How did you end up moving to the US?
I studied at the École Normale Supérieure 
in Paris, and in the summer after my sec-
ond year, I went to Angus Lamond’s lab at 
the EMBL in Heidelberg. I worked with 
one of his graduate students—Karsten 
Weis—on nuclear–cytoplasmic transport, 
an area that really fascinated me.
Later, as I was fi  nishing my undergrad-
uate degree, Karsten called me out of the 
blue and asked if I wanted to work for him 
in his own lab that he was starting at UCSF. 
Even though I had a PhD position lined 
up at the Pasteur Institute, it was a great 
opportunity. So I joined Karsten’s lab and 
began working on nuclear transport again, 
in particular on the small GTPase Ran.
The lab moved to Berkeley in the middle 
of my graduate studies and we ended up 
next door to Rebecca Heald, 
whose group works on mi-
totic spindle assembly. Just at 
that time, a string of papers 
came out suggesting that Ran 
was also involved in organiz-
ing the mitotic spindle—that 
it was generated in the vicin-
ity of chromatin to stabilize 
nearby microtubules. So we 
collaborated with Rebecca’s 
lab and made some really 
seminal discoveries. I found 
that the mechanism by which Ran functions 
in mitosis is essentially the same as its mech-
anism in interphase nuclear transport. It was 
a very exciting time where we went into a 
wide-open fi  eld and simply tested all the 
ideas that came into our heads.
Did you intend to continue working on 
mitosis as a postdoc with Peter Jackson?
Yes. After studying the basic principles of 
spindle assembly, I wanted to make a slight 
shift into studying how cells exit mitosis. 
It didn’t work out too well—I spent two 
years going nowhere. But it allowed me to 
slow down and open up to other ideas. I 
switched to cilia through a series of tenu-
ous molecular links between mitotic exit 
and an obscure disease called Almström 
syndrome. I was immediately fascinated 
by this disease, which has a variety of 
symptoms including retinal degeneration, 
obesity, and kidney malformation.
I couldn’t fi   gure out anything about 
the molecular basis of this disease. Then I 
read that it was similar to another disease 
called Bardet-Biedl syndrome, which had 
been linked to dysfunction of the primary 
cilium. I had never heard of primary cilia 
before! Few cell biologists were talking 
about it at the time and those that did 
thought it was just a remnant of evolution-
ary history—sort of like a cellular appendix. 
But now it was linked to human disease, and 
Kathryn Anderson published a paper show-
ing that primary cilia were essential for 
Hedgehog signaling. Something clicked in 
my head, and I decided to work on Bardet-
Biedl syndrome with the tools that I had, 
purifying protein complexes and setting 
up assays to study the cell biology of pro-
teins mutated in the disease.
TO INDUSTRY AND BACK
By that time you’d moved to Genentech?
Yes, it was right at the time that Peter took 
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a job at Genentech to lead a program on 
cell cycle regulation. He announced to the 
lab that he wanted everyone to come along. 
My wife worked for Genentech—she still 
does—so it was exciting to work closer to 
her, but I was very nervous about leaving 
academia. I had always envisioned an aca-
demic career for myself, and I just couldn’t 
see academic research being pursued in 
biotech. But Peter is a very convincing per-
son, and I ended up follow-
ing him. It turned out that I 
loved the place: there were 
almost limitless resources 
and some fantastic people to 
collaborate with. There was 
a great willingness to work 
together, and a general ex-
citement about the research we were doing. 
All the things you’d want in an academic 
department were right there at Genentech.
Were you tempted to stay?
Not really. As postdocs, we had free reign 
to do all the cool science we wanted. Our 
only brief was to publish great papers. But 
starting a lab at Genentech is a different 
experience—there’s more of an obligation 
to do something that could lead to potential 
therapies in the medium-term. I couldn’t 
see myself doing that. I just wanted to an-
swer all the incredibly exciting questions 
ahead of us in primary cilium research.
Let’s talk about that research. Why does 
Bardet-Biedl syndrome have such a wide 
range of symptoms?
That’s what fascinated me the most to 
start with. How can the loss of a single 
gene product make you unable to sense 
odors, make your retina degenerate, make 
you obese, make you grow extra digits, 
and make your kidneys fail? I don’t know 
any other disease where a single mutation 
causes such diverse symptoms.
During my postdoc, I found that most 
of the proteins mutated in Bardet-Biedl 
syndrome assemble into a protein complex 
that we called the BBSome. And just re-
cently we showed that the BBSome forms 
a membrane coat similar to clathrin that 
carries membrane receptors to the primary 
cilium, where they transduce specifi  c sig-
nals. So the different signaling pathways 
regulating body weight, limb morphology, 
and so on might all be defective because 
their receptors don’t make it to the cilium 
in the absence of the BBSome.
We think the BBSome forms a mem-
brane coat that clusters receptors in the 
plasma membrane and transports them 
through the diffusion barrier that exists at 
the base of the cilium. An unsolved ques-
tion is whether the BBSome is strictly a 
planar coat or whether it 
forms a vesicle at some point. 
We’re trying to follow single 
receptors as they move to 
the cilium, and we hope that 
will tell us exactly where the 
BBSome is acting.
THE NEXT LEVEL
Bardet-Biedl syndrome isn’t the only 
disease associated with cilia. What 
are the organelle’s links to cancer?
There’s nothing defi  nitive yet, but it’s ap-
pealing to think that signaling cascades 
would be dysregulated by the absence of 
cilia. In polycystic kidney disease, which is 
caused by a loss of cilia function, the kidney 
cells divide more. That leads to cysts rather 
than a tumor, but it suggests that cilia loss 
could facilitate cancer progression.
A postdoc in my lab is working with a 
mouse model for pancreatic cancer in which 
you can follow the progression of normal 
ductal epithelia into full-blown adenocarci-
nomas. Even at the earliest stages of the 
most benign lesions, cells have already lost 
their cilia—before you see any hyperprolif-
eration. So now we’re trying to combine the 
loss of cilia with expression of the K-ras 
oncogene to test whether losing cilia speeds 
up the progression toward adenocarcinoma. 
The organelle itself might be a tumor sup-
pressor—I think that’s an area that will 
become very exciting in the next few years.
What else are you working on?
Ultimately, I want to take things to a 
structural and biophysical level. We’re 
currently working on the structure of the 
BBSome using cryo-electron microscopy 
and x-ray crystallography.
We’re also interested in the link between 
the BBSome and tubulin acetylation. We 
made the surprising observation a few years 
ago that when we depleted cells of a spe-
cifi  c BBSome subunit called BBIP10, cyto-
plasmic microtubules were no longer 
acetylated. Almost everything that’s been 
published says that tubulin acetylation 
does nothing, but we think that this modifi  -
cation is actually doing something very 
interesting and important.
What do you like to do outside the lab?
I used to do a lot of mountain climbing. I 
went to Ecuador and summited a 20,000-
foot volcano there. I also climbed a lot in 
the Sierras in California. It’s a great way 
to disconnect from the lab and get away 
from your email and everything else. I 
raced mountain bikes when I was a stu-
dent and postdoc as well. Now I have a 
young daughter, so that has defi  nitely cut 
down on these kinds of things. But I just 
took her hiking through Big Sur, and she 
loved it—she liked seeing all the wild 
animals and birds.
Now I go swimming pretty much ev-
ery day. I’m not competitive about it—I 
just do it for fun and to have a little break 
over lunch.
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